by 
Impingement syndrome refers to a collection of painful conditions affecting the shoulders that occur when the rotator cuff tendons are compressed or “pinched” between the humerus (upper arm bone) and coracoid process of the scapula (shoulder blade). Treatment for impingement syndrome involves non-surgical methods like physical therapy, activity modifications, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections in rare cases, and surgery if other treatment options fail. With increasing participation in sports and accidents at the workplace leading to shoulder injuries, the demand for effective impingement syndrome treatment options is rising at a rapid pace.
The global Impingement Syndrome Market is estimated to be valued at US$ 2,173.5 Mn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: The increasing prevalence of shoulder injuries is one of the major factors anticipated to drive the growth of the global impingement syndrome market over the forecast period. According to the statistics provided by the National Library of Medicine, about 44% to 87% of patients with rotator cuff tears are also diagnosed with shoulder impingement. Several other factors such as increasing participation in sports and exercise activities, road accidents and trauma cases, intensive manual labor at workplaces are fueling the incidence rates of shoulder injuries globally. Advanced treatment options coupled with the availability of minimally invasive surgical procedures are also expected to boost the market growth.
Porter’s Analysis
Threat of new entrants: Low economies of scale and differentiation in the market make entry difficult for new companies. Products require regulatory approvals which increase risks for new entrants.
Bargaining power of buyers: Buyers have moderate bargaining power due to established key players dominating the market. However, availability of substitutes provides buyers with alternatives.
Bargaining power of suppliers: Key companies source raw materials from a limited number of suppliers giving them stronger bargaining power. Stringent regulations also create supplier concentration.
Threat of new substitutes: Threat of substitutes is moderate as alternative treatment options are available, but none replicate benefits of impingement syndrome market products.
Competitive rivalry: The market has major key players like Thermo Fisher Scientific, GE Healthcare etc. However, differentiated products and services create competitive differentiation among rivals.
Key Takeaways
The global Impingement Syndrome market is expected to witness high growth at a CAGR of 7.8% during the forecast period of 2023 to 2030. The market was valued at US$ 2,173.5 Mn in 2024.
Regional analysis: North America dominates the market currently due to increasing prevalence of shoulder disorders and rising sports injuries. Asia Pacific is expected to grow at fastest rate led by China and India due to large population base and improving healthcare infrastructure.
Key players: Key players operating in the Impingement Syndrome market are Thermo Fisher Scientific Inc., GE Healthcare, Merck KGaA, Bio-Rad Laboratories, Inc., Lonza, Abcam plc, PerkinElmer Inc., Bio-Techne, BioVision Inc., Cell Signaling Technology, Inc., and Geno Technology Inc. The players are focused on new product launches and geographical expansion to increase their market share.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
